The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
Level 5 - mechanism / opinion, no new human data
Narrative review and perspective containing no original empirical data or systematic search methodology.
PubMed 41545327 · doi:10.1002/cpdd.70001
What was done
Narrative review and perspective evaluating retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, and glucagon receptors, for the treatment of obesity, non-alcoholic steatohepatitis (NASH), and cardiovascular disease based on reported phase 2 clinical trials.
What was found
The abstract reports no numerical findings, statistical metrics, or effect sizes. It qualitatively describes phase 2 trial weight reductions as unprecedented and comparable to bariatric surgery, with additional reported benefits for NASH and cardiovascular comorbidities.
Why it matters
Highlights the emergence of multi-agonist peptide engineering as a potential paradigm shift in obesity management and metabolic disease pharmacotherapy.
Limits
This is a narrative perspective and review without original human data or systematic review methodology. The abstract provides no sample sizes, specific quantitative outcome metrics, safety or adverse event data, or long-term phase 3 trial evidence.
Cited by
- supports Retatrutide is a multi-agonist targeting GLP-1, GIP, and glucagon receptor pathways.